EDP-938, A Respiratory Syncytial Virus Antiviral, Demonstrates a High Barrier to Resistance in a Human Challenge Study
EDP-323, a First-in-Class, Once-Daily, Oral L-Protein Inhibitor for the Treatment of RSV: Results from a Phase 1 Study in Healthy Subjects and Correlation with In Vitro Antiviral Activity
HSD17B13 Inhibitors are Hepatoprotective and Anti-inflammatory in a Mouse Model of Autoimmune Hepatitis
Pharmacokinetics of EDP-323, a Potent, Once-Daily, Oral Antiviral Treatment for Respiratory Syncytial Virus
EDP-235, a Potent, Once-Daily, Oral Antiviral, Demonstrates Potential for Treatment and Prevention of Long COVID
EDP-235, an Oral 3CL Protease Inhibitor for the Treatment of COVID-19, Suppresses Viral Replication and Transmission in SARS-CoV-2-Infected Ferrets
High Throughput Screen to Identify Non-Nucleoside Small Molecule Inhibitors of SARS-CoV-2 RNA-Dependent RNA Polymerase
EDP-235, a Potent, Once-daily, Oral Antiviral, Demonstrates Excellent Penetration into SARS-CoV-2 Target Tissues, with the Potential for Mitigation of Viral Rebound in COVID-19 Patients
EDP-235, an Oral, Once Daily, Ritonavir-Free, 3CL Protease Inhibitor for the Treatment of COVID-19: Results from Phase 1 Study in Healthy Subjects